natgillin/translations-raw huggingface dataset:
Particular surface modifiers are selected from poloxamers, a-tocopheryl polyethylene glycol succinates, polyoxyethylene sorbitan fatty acid esters, and salts of negatively charged phospholipids or the acid form thereof. 
Pripravak mikro- ili nano-čestica kako je definirano u zahtjevu 5 naznačen time da je modifikator površine odabran od poloksamera, a-tokoferil polietilen glikol sukcinata, estera polioksietilen sorbitan masne kiseline, te soli negativno nabijenih fosfolipida ili njihovog kiselog oblika.
a pharmaceutically acceptable acid or base addition salt thereof, a quaternary amine thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N -oxide form thereof 
njihova farmaceutski prihvatljiva kisela ili bazična adicijska sol, njihov kvarterni amin, njihov stereokemijski izomerni oblik, njihov tautomerni oblik ili njihov N-oksidni oblik.
According to the present invention, the amount of levothyroxine sodium is 4 to 0.02 mg per 100 mg of the dry powder preparation, e.g. 
Prema predmetnom izumu, količina natrij levotiroksina je 4 do 0,02 mg po 100 mg pripravka suhog praha, npr.
The imprintable sheet or web material may further be of paper or of polymer (such as PE, PP or PVC), and it may comprise a single layer, as well as a plurality of layers. 
Materijali u obliku listova ili tkanina pogodnih za tiskanje mogu se izrađivati od papira ili polimera (materijali poput PE, PP ili PVC), a mogu se sastojati od jednog ili više slojeva.
In like manner to that described in Example 7 A-C and E, the named compound (cis-racemate) was prepared from commercially available 4,4'-dichlorobenzophencne (m.p. 300 - 301°C., elemental analysis calculated: 59.58% C; 5.29% H; 4.09% N; found: 59.64% C; 5.06% H; 4.13% N). 
Na sličan način s onim koji je opisan u primjeru 7 A-C i B, napravljen je imenovani spoj (cis-racemat) iz komercijalno pristupačnog 4,4'-diklorobenzofenona (t.t. 300-301*C, clementarna analiza izrač.: 59.58% C; 5.29% H; 4.09% N; nađeno: 59.64% C; 5.06% H; 4.13% N).
The composition as claimed in claim 2, wherein the microorganism is Rhizobium leguminosarum. 
Smjesa u skladu s patentnim zahtjevom 1, naznačena time što je mikroorganizam Rhizobium leguminosarum.
In another exemplary embodiment of the indexed drug delivery device, the indexed members are further predeterminately adapted to indicate an initial volume of approximately 32 L of compressible gas or 0.16 L of liquid. In another exemplary embodiment of the indexed drug delivery device, the API comprises carbon monoxide, the inactive carrier gas comprises O2 and, optionally the balance comprises N2, and, the canister concentration is in the range of approximately 500 ppm or 3000 ppm to 5000 ppm, 10,000 ppm, 15,000 ppm or 20,000 ppm. 
Indeksirani uređaj za ograničavanje sadržaja lijeka (24) prema zahtjevu 2, naznačen time da: aktivni farmaceutski sastojak sadrži dušikov oksid, neaktivni plin nosač sadrži N>, te je koncentracija u spremniku u rasponu od približno 50 ppm do 10,000 ppm, aktivni farmaceutski sastojak sadrži ugljikov monoksid, neaktivni plin nosač sadrži O,, te je koncentracija u spremniku (28) u rasponu od približno 500 ppm do 20,000 ppm, ili, aktivni farmaceutski sastojak je spoj halkogena u prikladnoj koncentraciji.
and R8 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, heterocycloalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, or and R8 may be taken together to form an optionally substituted monocyclic 4-8 membered saturated or unsaturated carbocyclic or heterocyclic ring, or an optionally substituted bicyclic 7-12 membered saturated or unsaturated carbocyclic or heterocyclic ring; 
i R8 su nezavisno vodik, alkil, supstituirani alkil, cikloalkil, supstituirani cikloalkil, aril, supstituirani aril, heteroaril, heterocikloalkil, heteroalkil, heteroalkenil, heteroalkinil, ili i R8 mogu biti zajedno uzeti da tvore izborno supstituirani monociklički 4-8 člani zasićeni ili nezasićeni karbociklički ili heterociklički prsten, ili izborno supstituirani biciklički 7-12 člani zasićeni ili nezasićeni karbociklički ili heterociklički prsten;
The present invention extends to the compound of formula I: 
HR P20151338 T1 PATENTNI ZAHTJEVI Spoj s formulom I:
A compound of any one of claims 1 to 7 for use in inhibiting tumor/cancer growth in a subject. 
Uporaba formule sukladno patentnom zahtjevu 1, radi pripreme medikamenta za spriječavanje proliferacije stanica tumora/raka kod pojedinca.
Netupitant for use according to claims 16-17, wherein said therapeutically effective amount of netupitant comprises from about 200 to about 400 mg. of netupitant or a pharmaceutically acceptable salt thereof, said therapeutically effective amount of 5-HT3 antagonist comprises from about 0.25 to about 0.75 mg. of palonosetron or a pharmaceutically acceptable salt thereof, and said therapeutically minimum effective dose of dexamethasone when administered alone comprises from about 16 mg to about 20 mg of dexamethasone. 
Netupitant za uporabu prema patentnim zahtjevima 16-17, naznačen time što navedena terapeutski efikasna količina netupitanta sadrži od oko 200 do oko 400 mg netupitanta ili njegove farmaceutski prihvatljive soli, pri čemu navedena terapeutski efikasna količina 5-HTs antagonista sadrži od oko 0.25 do oko 0.75 mg palonosetrona ili njegove farmaceutski prihvatljive soli, i navedena terapeutski minimalna efikasna doza deksametazona kada se primjenjuje pojedinačno također sadrži od oko 16 mg do oko 20 mg deksametazona.
A compound according to Formula I or a pharmaceutically acceptable salt thereof wherein 
HR P20190483 T1 PATENTNI ZAHTJEVI Spoj prema Formuli I
The connector unit in accordance with claim 10 further comprising a gas-tight compartment in the ozone device. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je dodatno vremenski raspored dezinfekcije podešen na ozonskom uređaju (100) mjeračem vremena.
High five cells expressing A2A receptors were homogenized in 50 mM tris-buffer pH 7.4 in an ultra Turrax homogenisator. 
Visoko Pet stanična ekspresija A,, receptora se homogenizira u 50 mM tris-puferu pH 7.4 u ultra Turrax homogenizatoru.
an amount of G2 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of said antibody molecules in said antibody molecule composition which is at least 50% higher compared to the same amount of antibody molecules in at least one antibody molecule composition of the same antibody molecule isolated from CHOdhfr- [ATCC No. 
(ii) količinu G2 struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 50% veća u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
The method of claim 3 wherein candesartan is administered in the form of candesartan cilexetil. 
Kombinacija prema zahtjevu 5, naznačena time da je kandesartan u obliku kandesartan cilekstila.
Yet another embodiment is said compounds of the invention for use in a method of treating cells or tissue involved in a pathology characterized by abnormal neuronal function in a subject. 
Spoj u skladu s patentnim zahtjevom 1, namijenjen upotrebi kao medikament za liječenje stanica ili tkiva uključenog u patologiju, naznačen time što postoji abnormalna funkcija neurona kod subjekta.
Group 1 (n=5) received standard maintenance diet for 75 days; group 2 (n=16) received the same diet but supplemented with 1% (wt/wt) cholesterol for 45 days. 
Skupina 1 (n=5) primala je standardnu dijetu 75 dana; skupina 2 (n-16) primala je istu dijetu ali nadopunjenu s 1% (masa/masa) kolesterola kroz 45 dana.
A pharmaceutical composition comprising a compound as claimed by any one of Claims 1 to 9 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, diluent, or excipient. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili njegovu farmaceutski prihvatljivu sol, kao i najmanje jednu farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
The water vehicle of claim 4, wherein the frame comprises a mounting bracket arranged to support an auxiliary device mounted thereon, wherein the auxiliary device comprises a light. 
Plovilo iz zahtjeva 4, naznačeno time da okvir (114) čine nosači za montiranje raspoređeni da podupiru pomoćnu napravu montiranu na njega.
Microparticles according to any preceding claim wherein the cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] is an amourphous powder having a particle size less than about 5 microns. 
Mikročestice u skladu s bilo kojim prethodnim zahtjevom, naznačene time, da ciklo[(4Â«(NH>-C>Hu-NH-CO-O-)Proj-Phg-DTrp-Lys-Tyr(4-Bzl)Phe] je amorfni prašak koji ima veličinu čestica manju od oko 5 mikrona.
In another embodiment of the invention there is provided a use of the vaccines of the invention in the manufacture of a medicament for the treatment or prevention of diseases caused by infection by poliovirus and optionally Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Hepatitis B virus, Haemophilus influenzae, Neisseria meningitidis type A, Neisseria meningitidis type C, Neisseria meningitidis type W, Neisseria meningitidis type Y, Salmonella typhi or Hepatitis A. 
Upotreba cjepiva u skladu s patentnim zahtjevima 1-8, naznačena time što je navedeno cjepivo namijenjeno proizvodnji međikamenta za sprječavanje bolesti koju uzrokuje poliovirus, te bakterije Clostridium tetani, Corynebacterium diphtheriae i Bordetella pertussis, te izborno jedno ili više između virusa hepatitisa B, bakterija Haemophilus influenzae B, Neisseria meningitidis tip A, Neisseria meningitidis tip C, Neisseria meningitidis tip W, Neisseria meningitidis tip Y, Neisseria meningitidis tip B, Salmonella typhi, te virusa hepatitisa A.
A product for use according to claim 19, wherein the disease is chronic obstructive pulmonary disease (COPD) and/or asthma. 
Proizvod namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što je namijenjen liječenju kronične opstruktivne plućne bolesti (COPD).
The amount of IFN-Y produced by the treated cells was calculated by interpolating the y values (O.D.) 
Količina INF-y proizvedena od strane tretiranih stanica bila je izračunata interpolacijom vrijednosti y (O.D.)
The thermoplastic film according to any preceding numbered embodiment, wherein the maximum average diameter of the fibres does not vary by more than 75%, preferably by more than 50%, more preferably by more than 25%, more preferably by more than 10%, from the minimum average diameter of the fibres. 
Termoplastična folija sukladno bilo kojem od prethodnih zahtjeva, pri čemu maksimalni prosječni promjer vlakana ne varira više od 75%, poželjno više od 50%, bolje više od 25%, najbolje više od 10%, od minimalnog prosječnog promjera vlakana.
In another embodiment of the foregoing, the optimized polynucleotide encodes an XTEN sequence with at least about 90% sequence identity to AM48. 
Fuzijski protein prema zahtjevu 4, naznačen time, da obuhvaća aminokiselinsku sekvencu koja ima najmanje 90% identiteta od aminokiselinske sekvence od
Ra is selected from hydrogen and a non-aromatic C1-4 hydrocarbon group; Rb is a non-aromatic C1-4 hydrocarbon group which is optionally substituted with one or more groups selected from fluorine; chlorine; bromine; cyano; hydroxy; methoxy; amino; or a cycloalkyl, heterocycloalkyl, aryl or heteroaryl group; 
Rb je nearomatska C1-4 ugljikovodična skupina koja se opcijski supstituira s jednom ili više skupina odabranih između fluorove; klorove; bromove; cijano; hidroksi; metoksi; amino ili cikloalkilne, heterocikloalkilne, arilne ili heteroarilne skupine; a isprekidana linija označava opcijsku drugu ugljik-ugljik vezu, pod uvjetom da kada postoji druga ugljik-ugljik veza nema R3.
Two adjacent seats 12 a, 12 b are separated by a partition 24 fitted with a through connector 26 having a first end 26 a facing sunken seat 12 a, and a second end 26 b facing seat 12 b. 
Dva susjedna sjedišta 12a, 12b su odijeljena pregradom 24, koja je prilagođena konektoru 26 koji prolazi kroz nju i ima prvi kraj 26a koji gleda prema upuštenom sjedištu 12a i drugi kraj 26b koji gleda prema sjedištu 12b.
The abovementioned rodent model was used to assess the effects of the Isomer A on sub-chronic PCP-induced deficits in working memory using the novel object recognition (NOR) paradigm. 
Gore navedeni model glodavca se koristio za ocjenjivanje učinaka Izomera A na sub-kroničan PCP-potaknut deficit radne memorije korištenjem obrasca prepoznavanja novog predmeta (NOR).
The proton NMR spectrum (DMSO-d6) was consistent with the proposed structure. 
Protonski NMR spektar (DMSO-d;) konzistentan je sa pretpostavljenom strukturom.
represents aluminium, magnesium, zinc, lithium; R1 represents a linear or branched C1-C20 alkyl group; m is 1, 2 or 3; 
- M, predstavlja aluminij, magnezij, cink, litij; RI predstavlja linearnu ili razgranatu C;-C2g alkil grupu; m je 1, 21li 3;
The cell according to claim 3, wherein the cell comprises the nucleotide sequence as an introgressed region. A method for producing a transgenic plant cell, wherein the method comprises a step of introducing the nucleic acid molecule according to claim 1 into the plant cell. 
Postupak dobivanja transgene biljne stanice, naznačen time što se postupak sastoji u koraku uvođenja molekule nukleinske kiseline u skladu s patentnim zahtjevom 1 ili vektora u skladu s patentnim zahtjevom 2 u biljnu stanicu.
The pharmaceutical composition according to claim 19, wherein said inflammatory disorder is selected from the group consisting of atherosclerosis, inflammation of the eye including uveitis, iritis, iridocyclitis, alcoholic hepatitis, allograft transplantation, xenograft transplantation, glomerulonephritis, reperfusion injury and acute inflammatory conditions following myocardial infarction and stroke. 
Farmaceutski pripravak za uporabu prema zahtjevu 18, gdje je navedena upalna bolest izabrana iz skupine koja se sastoji od ateroskleroze, upale oka uključujući uveitis, iritis, iridociklitis, alkoholnog hepatitisa, transplantacije alografta, transplantacije ksenografta, glomerulonefritisa, reperfuzijske ozljede i akutnih upalnih stanja nakon infarkta miokarda i moždanog udara.
A method according to any of claims 1 to 3, wherein the axes of the first and second rotors are arranged such that a line drawn from the axis of the first rotor to the axis of the second rotor makes an angle of from 0 to 20º, below the horizontal. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, pri čemu su osi prvog i drugog rotora raspoređene tako da linija koja se vuče od osi prvog rotora do osi drugog rotora pravi kut od 0 do 20", ispod vodoravne.
<400> 26 A monoclonal antibody capable of binding to human GDF-15, or an antigen-binding portion thereof capable of binding to human GDF-15, wherein: the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 5 or an amino acid sequence at least 90% identical thereto, and wherein the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence at least 85% identical thereto, and wherein the antibody or the antigen-binding portion thereof is capable of inhibiting cancer growth in a mammal, or 
5 1li aminokiselinsku sekvencu koja je najmanje 90% identična s tim, i gdje varijabilna domena lakog lanca sadrži regiju CDR3 koja sadrži sekvencu aminokiselina SEQ ID NO: 7 ili s njima najmanje 85% identična aminokiselinska sekvenca, i gdje antitijelo ili njegov dio koji veže antigen može inhibirati rast raka kod sisavca, ili ii) vezanje se veže na konformacijski ili diskontinuirani epitop na humanom GDF-15 koji se sastoji od aminokiselinskih sekvenci SEQ ID NO: 25 i SEQ ID NO: 26, i gdje je antitijelo ili njegov dio koji veže antigen sposoban za inhibiranje rasta raka kod sisavaca.
The patient may be refractory to treatment by the pharmaceutical agent that was administered in the pre-treatment. 
Pacijent može imati odbojnost prema liječenju farmaceutskim agensom koji se davao u prethodnom liječenju.
and pharmaceutically-acceptable salts and/or solvates thereof, or according to Claim 6, wherein the compound of formula la is any compound selected from: 
HR P20171553 T1 ili prema zahtjevu 6, pri čemu spoj s formulom 1a je bilo koji spoj odabran iz skupa koji čine:
In a second class of this embodiment, about 10% to about 100% by weight of the crystalline monohydrate is present in the drug substance. 
U drugoj klasi ove implementacije, oko 10% do oko 100% težinski kristalnog monohidrata je nazočno u supstanci lijeka.
A method according to claim 1, wherein minimizing the evaporation of nitrogen-containing ammonia or another nitrogen compound generated by the sludge is effected by maintaining a moisture level and/or a temperature during the treatment with superheated steam. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 7, karakterizirana minimaliziranjem isparavanja amonijaka koji sadrži dušik ili drugih dušikovih tvari nastalih iz mulja održavanjem razine vlažnosti i/ili temperature za vrijeme tretiranja superzagrijanom parom.
The compound of claim 1, wherein R1 is H, and/or wherein R2 is H. 
Spoj prema zahtjevu 1, pri čemu Ri je H, i/ili pri čemu R2» je H.
If necessary, the pH of the solution is adjusted to 7.0 to 7.4 with a suitable base. 
Ukoliko je potrebno, pH otopine se namjesti na 7,0 do 7.4 pomoću odgovarajuće baze.
Known forms of strap are made from rubber or a similar material but this may involve manufacturing difficulties as, for various reasons, the main body of inhalers are often made of plastic. 
Poznati oblici vrpce su načinjeni od gume ili sličnog materijala što može rezultirati poteškoćama u proizvodnji budući da se, zbog različitih razloga, glavno tijelo inhalatora često izrađuje od plastike.
Purification by silica gel chromatography (50% EtOAc in hexanes gradient to 95% EtOAc in hexanes) gave 2-benryl-2,4,5,6-tetrahydro-cyclopentapyrawle-3-carboxylic acid amide (739 mg, 3.07 mmol, 18% yield) isolated as a white solid followed by 1-benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide (3.24 g, 13.4 mmol, 79% yield) isolated as a white solid. 
Pročišćavanje kromatografijom na silikagelu (50% EtOAc u heksanu gradijenta do 95% FtOAc u heksanu) daje amid 2-benzil-2,4,5,6-tetrahidro-ciklopentapirazol-3-karboksilne kiseline (739 mg, 3.07 mmol, 18 % prinosa) izoliran kao bijela krutina i nakon njega slijedi amid 1-benzil-1,4,5,6-tetrahidro-ciklopentapirazol-3-karboksilne kiseline (3.24 g, 13.4 mmol, 79 % prinosa) izoliran kao bijela krutina.
For example, the compounds may be recovered by distilling off the solvent from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract. 
Kao primjer, spojeve se može prikupiti destiliranjem otapala iz reakcijske smjese ili, po potrebi nakon destiliranja otapala iz reakcijske smjese, lijevanjem ostatka u vodu, zatim ekstrakcijom organskim otapalom koje se ne miješa s vodom, te destiliranjem otapala iz ekstrakta.
converting Compound 10 to Compound 6. 
(d) prevođenju Spoja 10 u Spoj 6.
A composition comprising compound 1, or a pharmaceutically acceptable salt thereof: 
Spoj izabran iz grupe koji se sastoji od: (nastavak) Ili njegova farmaceutski prihvatljiva sol.
The integrated circuit according to claim 1, wherein said controlling of the transmission power value of the A-SRS is initiated upon receiving higher layer control information. 
Postupak radio komunikacije sukladno zahtjevu 5, sadržeći primanje kontrolne informacije višeg sloja, naznačeno time da se navedeno upravljanje vrijednosti snage prijenosa A-SRS-a inicira nakon navedenog primanja kontrolne informacije višeg sloja.
The process of claim 10, wherein the mixing of step a comprises adding the amine to the herbicidal pyridine containing carboxylic acid until the pH reaches a value of about 5 to 6. 
Herbicidni pripravak u skladu s patentnim zahtjevom 2, naznačen time što se monoetanolamin dodaje u vodenu disperziju klopiralida dok pH ne dođe do vrijednosti od 5 do 6.
An aspect of the present invention provides compounds of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, 
Spoj, naznačen time, da ima formulu (1), ili njegovi stereoizomeri ili njegove farmaceutske prihvatljive soli, a2 R
applying the treatment to the tissue-engineered product; 
(a) primjene tretmana na produkt preinačenog-tkiva;
Multi-purpose truck (100) for re-establishment of safe and practicable road conditions, after car accidents, through cleaning of the road platform, according to previous claim 2, characterized in that further comprising: 
Višenamjenski kamion (100) za ponovno uspostavljanje sigurnih i prohodnih uvjeta na cesti nakon automobilskih nezgoda, čišćenjem cestovne plohe, prema prethodnom patentnom zahtjevu 2, naznačen time, da nadalje sadrži:
The optical device of claim 8 wherein the projected light is provided at a first angle relative to the input diffractive optical element and wherein light coupled out of the waveguide by the output diffractive optical element is also provided at the first angle. 
Optički uređaj u skladu s patentnim zahtjevom 8, naznačen time što je projicirano svjetlo pod prvim kutem u odnosu na ulazni difraktivni optički element (17; 42; 54), te što je svjetlo koje izlazi iz valovoda (12) uz pomoć izlaznog difraktivnog optičkog elementa također pod prvim kutem.
Description of the sequences: 
Datum objave europskog patenta:
Functionally active deglycosylated long pentraxin PTX3. 
Funkcionalno aktivni, deglikozilirani dugi pentraksin PTX3.
The solid formulation according to any of claims 2 to 9, characterized in that the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, glyceryl behenate, polyethylene glycol, stearic acid and talc. 
Kruti pripravak prema bilo kojem od zahtjeva 2 do 8, naznačen time, da je lubrikant odabran iz skupine koju čine magnezijev stearat, kalcijev stearat, gliceril behenat, polietilen glikol, stearinska kiselina i talk.
the solvent can be an aqueous basic solution; and 
(a) otapalo može biti vodena bazična otopina; i
An intraocular or contact lens comprising an ophthalmic device material formed by copolymerizing a composition comprising i) a device-forming monomer selected from the group consisting of acrylic monomers and silicone-containing monomers, and ii) a benzotriazole compound of the formula 
Materijal za očne naprave, naznačen time što sadrži benzotriazolski spoj u skladu s patentnim zahtjevom 1 i monomer za oblikovanje naprave kojeg se bira skupine koju čine akrilni monomeri i monomeri koji sadrže silikon.
Binding of the target antigen to the autoantibodies of interest in the biological sample is then detected to ascertain the presence or concentration of the autoantibodies of interest. 
Postupak detektiranja autoprotutijela u biološkom uzorku, gdje je navedeno autoprotutijelo specifično za ciljni antigen, naznačen time što se postupak sastoji u koracima:
The system of claim 4, wherein the light conduction device comprises at least one flection; and the light passing through the rear end lens group is directed to the light transmitting cylinder via a sidewall or a bottom of the light transmitting cylinder. 
Sustav prema bilo kojem od zahtjeva 2-4, naznačen time što uređaj za provođenje svjetlosti sadrži barem jednu fleksiju, a svjetlost koja prolazi kroz stražnju krajnju skupinu leća usmjerena je na cilindar koji odašilje svjetlost preko bočne stjenke ili njegovog dna.
The agent for use according to claim 4, wherein the agent is for treating pulmonary hypertension. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje plućne hipertenzije.